Valiant Organics Limited · NSE:VALIANTORG
Valiant Organics — Q3 FY2023 Earnings Presentation
25 slides from Valiant Organics's earnings presentation, Feb 1, 2023
Slide 1: Regulation 30 cover letter to stock exchanges
February 01, 2023 To, To, Listing/Compliance Department Listing/Compliance Department BSE LTD National Stock Exchange of Phiroze Jeejeebhoy Towers, India Limited Dalal Street, “Exchange Plaza”,Plot No.C/1, Mumbai- 400 001. G Block Bandra-Kurla Complex, Bandra (E), Mumbai- 400 051. BSE Code-540145 NS
Slide 2: Earnings Presentation | Q3/9M-FY23
Earnings Presentation | Q3/9M -FY23
Slide 3: Snapshot
SNAPSHOT One of the largest chlorophenol One of the leading manufacturer of derivatives manufacturer globally Benzene derivatives products One of the largest domestic PNA One of the few commercial players in manufacturer Ortho Anisidine and Para Anisidine Diversified client base across Amongst 1st f
Slide 4: Company Overview
Company Overview Valiant Organics Limited was incorporated in 1984 by first generation technocrats and is headquartered out of Mumbai, India. The company is focused on the manufacturing and marketing of specialty chemicals which find usage in a variety of industries, including agrochemicals, pharmac
Slide 5: Chemistries And Product Basket
Chemistries And Product Basket 9M-FY23 Revenue Share Hydrogenation Ammonolysis 46% Key Products: Industries Served: Key Products: • Ortho Anisidine • Dyes Industries Served: • Para Anisidine • Pigments • Para Nitro Aniline • Dyes • IPPCA • Pharmaceutical • Ortho Chloro Para Nitro Aniline • Pigments
Slide 6: Manufacturing Footprint
Manufacturing Footprint CHLORINATION – SARIGAM HYDROGENATION & METHOXYLATION- • Capacity: 18,000 MTPA JHAGADIA UNIT 1 • Products: PCP, OCP, 2,4 DCP, 2,6 DCP, • Capacity: 28,800 MTPA 2,4,6 TCP • Products: ONA/OA, PNA/PA, IPPCA, CONVERSION PRODUCTS AMMONOLYSIS - VAPI HYDROGENATION – JHAGADIA UNIT 2 •
Slide 7: Key Strengths
Key Strengths Domain expertise and broad Plant locations are process understanding in a Wide supply chain strategically located near variety of chemistries. The provides the continuous ports to provide a executive team is made up of availability of adequate competitive advantage, first-generation te
Slide 8: Capex Projects
Capex Projects Product Project Status Remarks Commissioned Para Nitro Aniline (PNA) & Ortho Chloro Completing phase-wise • Expansion from 550 TPM to 750 TPM at Vapi plant Para Nitro Aniline (OCPNA) • Full capacity addition in progress Ortho Nitro Anisole (ONA) Completed in Q4 FY’20 • Backward integr
Slide 9: Q3/9M-FY23 Highlights
Q3/9M-FY23 HIGHLIGHTS Valiant Organics Limited |February 2023 8
Slide 10: Consolidated Financial Highlights
CONSOLIDATED FINANCIAL HIGHLIGHTS Q3-FY23 Consolidated Financial Highlights 9M-FY23 Consolidated Financial Highlights INR 2,504 Mn INR 7,804 Mn Operational Revenue Operational Revenue INR 383 Mn INR 1,120 Mn Operating EBITDA Operating EBITDA 15.30% 14.35% Operating EBITDA Margin Operating EBITDA Mar
Slide 11: Q3/9M-FY23 Operational Highlights
Q3/9M-FY23 Operational Highlights • Q3-FY23 was a subdued quarter mainly due to low demand from dyes & pigment intermediates. Q3-FY23 Revenue Break-up – Chemistries Others, 5% • Margins improved marginally despite the drop in volume & revenue from the previous quarter. Ammonolysis, Chlorination, 23%
Slide 12: Key Chemistries: Sales Volumes and Revenues
Key Chemistries Chlorination Hydrogenation Ammonolysis Others REVENUES (INR Mn) 1,150 1,106 900 797 250 800 730 1,100 1,076 800 740 199 700 200 700 600 501 1,050 600 545 155 411 150 107 500 500 1,000 400 950 943 400 100 300 300 200 200 50 900 100 100 0 0 0 850 Q3-FY22 Q2-FY23 Q3-FY23 Q3-FY22 Q2-FY23
Slide 13: Quarterly Consolidated Financial Performance
Quarterly Consolidated Financial Performance Particulars (INR Mn) Q3-FY23 Q3-FY22 Y-o-Y Q2-FY23 Q-o-Q Revenue from Operations 2,504 2,884 (13.2)% 2,641 (5.2)% Total Expenses 2,121 2,382 (11.0)% 2,222 (4.5)% EBITDA 383 502 (23.7)% 419 (8.6)% EBITDA Margins (%) 15.30% 17.41% (211) bps 15.87% (57) bps
Slide 14: YTD Consolidated Financial Performance
YTD Consolidated Financial Performance Particulars (INR Mn) 9M-FY23 9M-FY22 Y-o-Y Revenue from Operations 7,804 8,056 (3.1)% Total Expenses 6,684 6,578 1.6% EBITDA 1,120 1,478 (24.2)% EBITDA Margins (%) 14.35% 18.35% (400) bps Other Income 52 52 0.0% Depreciation 212 212 0.0% Finance Cost 78 48 62.5
Slide 15: Quarterly Standalone Financial Performance
Quarterly Standalone Financial Performance Particulars (INR Mn) Q3-FY23 Q3-FY22 Y-o-Y Q2-FY23 Q-o-Q Revenue from Operations 2,176 2,608 (16.6)% 2,323 (6.3)% Total Expenses 1,893 2,162 (12.4)% 2,009 (5.8)% EBITDA 283 446 (36.5)% 314 (9.9)% EBITDA Margins (%) 13.01% 17.10% (409) bps 13.52% (51) bps Ot
Slide 16: YTD Standalone Financial Performance
YTD Standalone Financial Performance Particulars (INR Mn) 9M-FY23 9M-FY22 Y-o-Y Revenue from Operations 6,844 6,579 4.0% Total Expenses 5,985 5,373 11.4% EBITDA 859 1,206 (28.8)% EBITDA Margins (%) 12.55% 18.33% (578) bps Other Income 23 46 (50.0)% Depreciation 201 200 0.5% Finance Cost 76 46 65.2%
Slide 17: Historical Financial Overview
HISTORICAL FINANCIAL OVERVIEW Valiant Organics Limited |February 2023 16
Slide 18: Historical Consolidated Income Statement
Historical Consolidated Income Statement Particulars (INR Mn) FY20 FY21* FY22* 9M-FY23* Operational Income 6,749 7,548 11,533 7,804 Total Expenses 4,946 5,496 9,484 6,684 EBITDA 1,803 2,052 2,049 1,120 EBITDA Margins (%) 26.71% 27.19% 17.77% 14.35% Other Income 63 59 74 52 Depreciation 158 212 296 2
Slide 19: Consolidated Balance Sheet (IND-AS)
Consolidated Balance Sheet (IND – AS) Particulars (INR Mn) FY21 FY22 H1-FY23 Particulars (INR Mn) FY21 FY22 H1-FY23 EQUITY 5,086 6,489 6,816 Non-Current Assets 5,731 6,652 7,000 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,967 5,303 5,375 b) Other Equity 4,747 5,856 6,121 b
Slide 20: Historical Standalone Income Statement
Historical Standalone Income Statement Particulars (INR Mn) FY20 FY21* FY22* 9M-FY23* Revenue from Operations 5,836 5,742 9,484 6,844 Total Expenses 4,103 4,170 7,834 5,985 EBITDA 1,733 1,572 1,650 859 EBITDA Margins (%) 29.69% 27.38% 17.40% 12.55% Other Income 52 169 56 23 Depreciation 130 186 273
Slide 21: Standalone Balance Sheet (IND-AS)
Standalone Balance Sheet (IND – AS) Particulars (INR Mn) FY21 FY22 H1-FY23 Particulars (INR Mn) FY21 FY22 H1-FY23 EQUITY 5,023 6,031 6,240 Non-Current Assets 5,798 6,787 7,094 a) Equity Share Capital 272 272 272 a) Property, Plant and Equipment 4,771 5,085 5,143 b) Other Equity 4,747 5,755 5,964 b)
Slide 22: Consolidated Financial Highlights
Consolidated Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 14,000 80.00% 1,400 1,282 1,309 1,279 2,052 2,049 11,533 2,100 70.00% 12,000 1,803 1,800 60.00% 1,100 10,000 7,548 7,804 1,500 50.00% 1,120 800 686 8,000 6,749 1,200 40.
Slide 23: Capital Market Information
Capital Market Information Share Price up to 31st December, 2022 30% 20% 10% 0% -10% -20% -30% -40% -50% -60% Jan-22 Feb-22 Mar-22 Apr-22 May-22 Jun-22 Jul-22 Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Valiant Organics - Closing Price Sensex Price Data (As on 31st December, 2022) INR Shareholding pattern (A
Slide 24: Disclaimer
Disclaimer Valiant Organics Limited No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all event
Slide 25: Thank You
THANK YOU Valiant Organics Limited |February 2023 24